Table 1:
Phenotypic and Growth Characteristics of CWR22, CWR22-RH, LvCaP-2, LvCaP-2R, SkCaP-1, SkCaP-1R, LNCaP, and LN-95.
| CWR22 | CWR22-RH | LvCaP-2 | LvCaP-2R | SkCaP-1 | SkCaP-1R | LNCaP | LNCaP-95 | |
|---|---|---|---|---|---|---|---|---|
| RNAseq Classification | AR+ PCa | AR+ PCa | AR+/NE+ PCa | AR+/NE+ PCa | AR+ PCa | AR+ PCa | AR+ PCa | AR+ PCa |
| Tissue of Origin | Primary | CWR22 | Liver Met | LvCaP-2 | Skin Met | SkCaP-1 | Lymph Node Met | LNCaP |
| Patient Treatment History | None | ADT, Abi, Carboplatin, and Enza | ADT, Taxane, Abi, Carboplatin, Enza | Castration | ||||
| Histology | Poorly Differentiated Adenocarcinoma | Poorly Differentiated Adenocarcinoma | Poorly Differentiated Amphicrine Carcinoma | Poorly Differentiated Amphicrine Carcinoma | Poorly Differentiated Adenocarcinoma | Poorly Differentiated Adenocarcinoma | Poorly Differentiated Adenocarcinoma | Poorly Differentiated Adenocarcinoma |
| in vivo Growth Response to ADT | Yes | No | Yes | No | Yes | No | Yes | No |
| Xenograft Doubling Time | 11 +/− 3 days (Intact Host) | 10 +/− 2 days (Intact or Castrate Host) | 10 +/− 3 days (Intact Host) | 9 +/− 2 days (Intact or Castrate Host) | 14 +/− 5 days (Intact Host) | 18 +/− 4 days (Intact or Castrate Host) | 12 +/− 5 days (Intact); 26 +/− 7 days (Castrate) | 6 +/− 3 days (Intact or Castrate Host) |
| AR | Homozygous GOF H878A mutation | Homozygous Double GOF H875Y & T878A mutation | Wild Type + low to no V7 | Wild Type + V7 | Wild Type | Wild Type + V7 | Homozygous T878A GOF mutation | Homozygous T878A GOF mutation + V7 |
| Normalized AR mRNA | 4 | 11 | 52 | 256 | 4 | 388 | 17 | 30 |
| Normalized AR protein | 6 | 25 | 11 | 50 | 7 | 80 | 33 | 59 |
| AR-FL/AR-V7 protein ratio | >100:1 | >100:1 | >100:1 | 6:1 | >100:1 | 12:1 | >100:1 | 8:1 |
| TP53 | Heterozygous LOF G154F mutation | Heterozygous LOF G154F mutation | LOF T211fs mutation | LOF T211fs mutation | Wild Type | Wild Type | Wild Type | Wild Type |
| PTEN | Wild Type | Heterozygous LOF T321fs mutation | LOH & Hemizygous Deleterious R130Q mutation | LOH & Hemizygous Deleterious R130Q mutation | Homozygous Deletion | Homozygous Deletion | LOH & Hemizygous p.K6fs Deleterious AA mutation | LOH & Hemizygous p.K6fs Deleterious AA mutation |
| ERG | No | No | No | No | Yes | Yes | No | No |
| c-Myc | >80% | >85% | >80% | >50% | >40% | >60% | >50% | >75% |
| Nkx3.1 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Ki67 | 72 +/− 27% | 83 +/− 6% | 80 +/− 6^ | 75 +/− 9% | 45 +/− 3% | 39 +/− 4% | 47 +/− 12% | 82 +/− 12% |
| PSA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Serum PSA (ng/mL/g) | 462 +/− 67 (Intact Host) |
249 +/− 41 (Castrate Host) | 59 +/− 11 (Intact Host) |
25 +/− 6 (Castrate Host) |
284 +/− 51 (Intact Host) |
44 +/− 12 (Castrate Host) |
185 +/− 34 (Intact Host) |
50 +/− 10 (Castrate Host) |
| PSMA | Yes | Yes | Focal | Focal | >50% | >50% | Yes | Yes |
| CK5 | No | No | No | No | No | No | No | No |
| CK18 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| B-catenin | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type |
| RB | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type |
| ChgA | No | No | Yes | Yes | No | No | No | No |
| HoxB13 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| TP63 | No | No | No | No | No | No | No | No |
| Sox2 | No | No | No | No | No | No | No | No |
| BRCA2 | Heterozygous LOF E984fs mutation | Heterozygous LOF E984fs mutation | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type |
| PIK3CA | Heterozygous Q546R mutation | Heterozygous Q546R mutation | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type |
| MSH2 | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | Wild Type | MSI, Homozygous Deletion | MSI, Homozygous Deletion |